Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;28(11):1123-1133.
doi: 10.1007/s11916-024-01290-y. Epub 2024 Jul 2.

Animal Models of Chronic Migraine: From the Bench to Therapy

Affiliations
Review

Animal Models of Chronic Migraine: From the Bench to Therapy

Wei Zhang et al. Curr Pain Headache Rep. 2024 Nov.

Abstract

Purpose of review: Chronic migraine is a disabling progressive disorder without effective management approaches. Animal models have been developed and used in chronic migraine research. However, there are several problems with existing models. Therefore, we aimed to summarize and analyze existing animal models to facilitate translation from basic to clinical.

Recent findings: The most commonly used models are the inflammatory soup induction model and the nitric oxide donor induction model. In addition, KATP openers have also been used in model induction. Based on the above models, some molecular targets have been identified, such as glutamate receptors. However, each model has its shortcomings and characteristics, and there are still some common problems that need to be solved, such as spontaneous headache, evaluation criteria after model establishment, and identification methods. In this review, we summarized and highlighted the advantages and limitations of the currently commonly used animal models of chronic migraine with a special focus on drug discovery and current therapeutic strategies, and discussed the directions that can be worked on in the future.

Keywords: Animal models; Chronic migraine; Headache; Therapeutic medicine.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ferrari MD, Goadsby PJ, Burstein R, et al. Migraine. Nat Rev Dis Primers. 2022;8(1):2. Published 2022 Jan 13. https://doi.org/10.1038/s41572-021-00328-4 .
    1. Schwedt TJ. Chronic migraine. BMJ. 2014;348:g1416. Published 2014 Mar 24. https://doi.org/10.1136/bmj.g1416 .
    1. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019;37(4):631–49. https://doi.org/10.1016/j.ncl.2019.06.001 . - DOI - PubMed
    1. Zobdeh F, Ben Kraiem A, Attwood MM, et al. Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol. 2021;178(23):4588–607. https://doi.org/10.1111/bph.15657 . - DOI - PubMed
    1. Kuruvilla DE, Bilchik T. Preventing the Progression of Episodic Migraine to Chronic Migraine with Acute Treatment Optimization. Curr Pain Headache Rep. 2022;26(3):253–8. https://doi.org/10.1007/s11916-022-01022-0 . - DOI - PubMed

LinkOut - more resources